Danaher Co. (NYSE:DHR) Shares Sold by Stock Yards Bank & Trust Co.

Stock Yards Bank & Trust Co. cut its holdings in Danaher Co. (NYSE:DHR) by 1.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 116,496 shares of the conglomerate’s stock after selling 1,466 shares during the period. Stock Yards Bank & Trust Co.’s holdings in Danaher were worth $29,107,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Tsfg LLC lifted its stake in Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares during the last quarter. nVerses Capital LLC purchased a new stake in shares of Danaher during the 2nd quarter worth approximately $25,000. CarsonAllaria Wealth Management Ltd. acquired a new position in shares of Danaher in the 2nd quarter valued at $25,000. Cape Investment Advisory Inc. purchased a new position in shares of Danaher in the 4th quarter valued at $25,000. Finally, Redmont Wealth Advisors LLC acquired a new stake in Danaher during the 1st quarter worth $30,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Danaher

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock worth $11,042,433 over the last 90 days. Company insiders own 11.10% of the company’s stock.

Danaher Price Performance

Shares of DHR opened at $276.06 on Tuesday. The firm has a market capitalization of $199.37 billion, a PE ratio of 46.79, a P/E/G ratio of 4.48 and a beta of 0.83. The stock’s 50 day moving average is $265.25 and its two-hundred day moving average is $256.67. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s quarterly revenue was down 2.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.05 earnings per share. Research analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a $0.27 dividend. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. Danaher’s dividend payout ratio is presently 18.31%.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 price objective on shares of Danaher in a report on Friday, September 6th. The Goldman Sachs Group lifted their price target on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Jefferies Financial Group assumed coverage on Danaher in a report on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective for the company. Stifel Nicolaus lifted their target price on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Finally, Wells Fargo & Company initiated coverage on shares of Danaher in a research note on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target for the company. Seven research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $278.94.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.